Fusidic acid in septicaemia and endocarditis.
The in vitro activity of fusidic acid against Staphylococcus aureus is confirmed in clinical studies which demonstrate that this antibiotic in combination with other agents, particularly beta-lactams, is efficacious in non-MRSA septicaemia. Some reports suggest that fusidic acid when used in combination, may significantly diminish the risk of relapse after cessation of therapy. However, in spite of over 30 years of use and its recommendation in a number of guidelines, published evidence is insufficient to allow reliable comment on the efficacy of the antibiotic in the treatment of endocarditis.
Whitby
M
M
Department of Infectious Diseases, Infection Control and Sexual Health, Princess Alexandra Hospital, Brisbane, Queensland, Australia. whitby@health.qld.gov.au
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004696:Endocarditis / Q000188:drug therapy*; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007769:Lactams; D018805:Sepsis / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D007769:Lactams; D005672:Fusidic Acid